-
Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines
•
Shanghai-based Alebund Pharmaceuticals has announced the completion of a Series C financing round, raising RMB 550 million (USD 75.04 million). The round was led by Yangzhou Guojin Investment Group Co. Ltd and Kingray Capital, both renowned healthcare funds. The proceeds will be used to enhance the development and commercialization of…
-
Shengwei Kunteng Raises RMB 200 Million in Series A Financing for POCT Development
•
China-based Hunan Shengwei Kunteng Biotechnology Co., Ltd has announced that it has raised close to RMB 200 million (USD 27.3 million) in a Series A financing round led by Sansure, Sanway Spring, and Voyagers Capital. The funds will be directed towards research and development and the construction of an industrialization…
-
Hangzhou Highlightll Pharma Completes Pre-Series C Financing Round
•
China-based Hangzhou Highlightll Pharmaceutical Co., Ltd has announced the successful completion of a Pre-Series C financing round, raising RMB 150 million (USD 20.5 million). The investment was led by Huajin Capital, Bayland Capital, Infinity Capital, and returning investor Hankang Capital. The funds will be used to enhance the clinical development…
-
Milestone Biotechnologies Secures Nearly 100 Million Yuan in Series A+ Funding
•
Milestone Biotechnologies, a leading biotechnology company based in Shanghai, has announced the completion of a nearly 100 million yuan Series A+ funding round. The round was led by Xingzheng Capital, with participation from Ji Gao Financial Company and Nanjing Innovation Investment Group. Kaideng Capital continued to serve as the exclusive…
-
Prime Gene Therapeutics Secures Over RMB300 Million in Series B Financing
•
Beijing-based Prime Gene Therapeutics Co., Ltd (873969.NQ), a clinical-stage biotech company specializing in immune inflammatory diseases, has reportedly raised over RMB300 million (USD41 million) in a Series B financing round. The investment was led by a consortium of prominent financial backers, including Beijing Medical and Health Industry Investment Fund, E-town…
-
Maxvax Biotechnology Secures RMB 200 Million in Convertible Bonds Financing
•
Immunotherapy biotech company Maxvax Biotechnology, based in Chengdu, has announced the successful closure of a convertible bonds financing round, raising RMB 200 million (USD 27.4 million). The financing was subscribed to by the Shenzhen Capital Group Manufacturing Industry Transformation and Upgrading New Materials Fund, highlighting the investor’s confidence in Maxvax’s…
-
Shinva Medical Instrument to Acquire Stake in Wuhan Zhongzhi Biotechnologies for IVD Expansion
•
China’s Shinva Medical Instrument Co., Ltd (SHA: 600587) has announced its intention to acquire a significant stake in Wuhan Zhongzhi Biotechnologies Inc. (836834), purchasing 36.1913% of the company’s shares for RMB166.5 million (USD22.8 million). Zhongzhi Bio’s Focus on RNA Molecule IVD KitsFounded in 2011, Zhongzhi Bio is a company dedicated…
-
Reforgene Medicine Secures Hundreds of Millions in Financing for Gene Therapy Expansion
•
Reforgene Medicine, a prominent gene editing therapy company headquartered in Guangzhou, has reportedly secured hundreds of millions of renminbi in a new financing round. This funding round was led by Guangzhou Industry Investment, with additional contributions from Guangzhou Financial Holdings, Technology Financial Holdings, and returning investor IFSC. The capital raised…
-
GenFleet Therapeutics Submits IPO Application to HKEX, Backed by CITIC Securities
•
On December 27, 2024, GenFleet Therapeutics, a biopharmaceutical company based in Shanghai, submitted its application for listing on the Hong Kong Stock Exchange (HKEX), with CITIC Securities serving as the exclusive sponsor and overall coordinator. Company Background and FocusEstablished in 2017, GenFleet Therapeutics is a market-stage biopharmaceutical company specializing in…
-
Overwhelming Shareholder Support for Hengrui Pharmaceuticals’ H-Share IPO
•
On December 26, Hengrui Pharmaceuticals (SHA: 600276) held its second extraordinary general meeting of 2024, where the primary agenda was to discuss the company’s proposal to issue H shares and list them on the Hong Kong Stock Exchange (HKEX). Landmark Approval for H-Share IssuanceThe outcome of the deliberation was overwhelmingly…
-
Dynamiker Biotechnology Receives Approval for IPO on Beijing Stock Exchange
•
On December 27, 2024, the official website of the Beijing Stock Exchange announced that Dynamiker Biotechnology (Tianjin) Co., Ltd. has received approval for its initial public offering (IPO) from the listing committee, with Citic Securities serving as the sponsor. The company aims to raise RMB 456 million (approximately USD 64…
-
AusperBio Secures $73 Million in Series B Financing to Advance Hepatitis B Therapy
•
Sino-US liver therapy developer AusperBio has announced the completion of a USD 73 million Series B financing round, following a USD 37 million Series A funding in July this year. This latest round was led by HanKang Capital, with participation from Sherpa Capital, CDH Investments, and a strategic investor, along…
-
Zhejiang Huahai Pharmaceutical’s Subsidiary Huaota Bio Secures $27.4 Million Investment
•
Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that its macromolecular drug-focused subsidiary, Shanghai Huaota Biopharmaceutical Co., Ltd., has successfully raised RMB 200 million (USD 27.4 million) through a new issuance of 20 million shares. The shares were exclusively subscribed by Linhai Haijing Venture Capital. This transaction has increased…
-
uBriGene Secures RMB 200 Million in Pre-Series D Financing to Expand ATMPs CDMO Services
•
China-based uBriGene, a contract development and manufacturing organization (CDMO) focused on advanced therapy medicinal products (ATMPs), has announced the completion of its Pre-Series D financing round, raising close to RMB 200 million (USD 27.4 million). This funding round comes on the heels of the Series C+ financing round completed in…
-
Ikena Oncology and Inmagene Biopharmaceuticals to Merge into ImageneBio, Listed on Nasdaq as ‘IMA’
•
US-based Ikena Oncology, Inc. (NASDAQ: IKNA) and Sino-US biotech Inmagene Biopharmaceuticals have announced their merger to form a new entity, ImageneBio, which will be listed on Nasdaq with the ticker symbol “IMA”. Focused Development on IMG-007 Post-MergerThe newly merged company, ImageneBio, will concentrate its efforts on the development of IMG-007,…
-
C.Q. Pharmaceutical Holding to Come Under SASAC’s Indirect Control via Genertec Acquisition
•
C.Q. Pharmaceutical Holding Co., Ltd (SHE: 000950), a Chongqing-based pharmaceutical company, is set to be indirectly controlled by China’s State-owned Assets Supervision and Administration Commission of the State Council (SASAC). The company has entered into an acquisition agreement with China General Technology (Group) Holding Co Ltd (Genertec), a centrally administered…
-
Biopharma Company TransThera Sciences (Nanjing) Gets Green Light for HK IPO
•
On December 20, 2024, the China Securities Regulatory Commission confirmed the listing filing for TransThera Sciences (Nanjing), Inc., to proceed with its initial public offering (IPO) in Hong Kong. Proposed Share Issuance and ConversionTransThera Sciences plans to issue up to 146 million overseas-listed ordinary shares on the Hong Kong Stock…
-
Wuhan Weike Medical Technology Secures Series C Funding to Boost Cardiovascular Innovation
•
Wuhan Weike Medical Technology Co., Ltd., known as “Weike Medical,” has officially announced the successful completion of its Series C financing round, raising several hundred million RMB led exclusively by Bohua Capital, a renowned investment institution in Liangxi District, Wuxi. This funding will provide robust financial support for Weike Medical…
-
HealthyWay Inc. Completes HKD 220 Million IPO on the Hong Kong Stock Exchange
•
China-based HealthyWay Inc. (HKG: 2587) has made a significant debut on the Hong Kong Stock Exchange with an initial public offering (IPO) of 25 million shares, priced at HKD 8.8 per share. This translates to a capital raise of HKD 220 million (USD 28.3 million), marking a significant milestone for…
-
MicroPort NeuroTech Leads Investment Fund to Advance Brain Science Industry
•
China-based MicroPort NeuroTech Limited (HKG: 2172) has announced its commitment to invest RMB 200 million (USD 27.46 million) to jointly establish an investment fund aimed at fostering the development of the brain science and brain-Inspired Intelligence industry, aligning with MicroPort NeuroTech’s strategic future direction. Collaboration with Other InvestorsJoining MicroPort NeuroTech…
